España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AbbVie
ABBV
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$203.87
2.37
1.18%
At close: -
$203.10
-0.77
-0.38%
After Hours: 7:08 PM EDT
15 minutes delayed
Get Report
Comment
Q3 2024 Earnings were released on Wed Oct 30th, before the market open
The most recent conference call was at 9:00 AM, 1 day ago
Click to view past webcast
Aliada announced it will be acquired by AbbVie (ABBV) on Monday, October 28, 2024 for $1.4B paid in cash
AbbVie (ABBV) Forecast
News
Earnings
AbbVie (ABBV) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for AbbVie (NYSE:ABBV) Stock
AbbVie Stock (NYSE: ABBV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, October 31, 2024
Citigroup Maintains Buy on AbbVie, Raises Pri...
Benzinga Newsdesk
UBS Maintains Neutral on AbbVie, Raises Price...
Benzinga Newsdesk
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Benzinga Insights
Morgan Stanley Maintains Overweight on AbbVie...
Benzinga Newsdesk
AbbVie, EvolveImmune Therapeutics Announce Op...
Benzinga Newsdesk
Wednesday, October 30, 2024
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Vandana Singh
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Piero Cingari
AbbVie's Options Frenzy: What You Need to Know
Benzinga Insights
AbbVie shares are trading higher after the co...
Benzinga Newsdesk
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
Vandana Singh
AbbVie Executive Says Company Cut 2024 U.S. H...
Benzinga Newsdesk
AbbVie Executive Says Now Expect Skyrizi Glob...
Benzinga Newsdesk
Abbvie Exec Says Company Now Seeing More Humi...
Benzinga Newsdesk
AbbVie Raises Its Adjusted EPS Guidance For 2...
Benzinga Newsdesk
AbbVie Q3 2024 Adj EPS $3.00 Beats $2.92 Esti...
Benzinga Newsdesk
Tuesday, October 29, 2024
AbbVie Small Cell Lung Cancer Treatment (An A...
Benzinga Newsdesk
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
Surbhi Jain
AbbVie's VRAYLAR Now Publicly Reimbursed In O...
Benzinga Newsdesk
Monday, October 28, 2024
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
Avi Kapoor
AbbVie To Acquire Aliada Therapeutics For $1....
Benzinga Newsdesk
Friday, October 25, 2024
Forecasting The Future: 11 Analyst Projections For AbbVie
Benzinga Insights
Citigroup Maintains Buy on AbbVie, Raises Pri...
Benzinga Newsdesk
CNBC Halftime Report Final Trades: Tesla, Swe...
Benzinga Newsdesk
Thursday, October 24, 2024
Check Out What Whales Are Doing With ABBV
Benzinga Insights
AbbVie And Gedeon Richter Enter New Collabora...
Benzinga Newsdesk
Monday, October 21, 2024
AbbVie Announces That 9 Canadian Provinces Ha...
Benzinga Newsdesk
REGENXBIO Reports Phase II Data for Wet AMD G...
Benzinga Newsdesk
Reported Friday, Allergan Aesthetics, An Abbv...
Benzinga Newsdesk
Friday, October 18, 2024
B of A Securities Maintains Neutral on AbbVie...
Benzinga Newsdesk
Thursday, October 17, 2024
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vandana Singh
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Benzinga Insights
BMO Capital Maintains Outperform on AbbVie, R...
Benzinga Newsdesk
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
Avi Kapoor
U.S. FDA Approves VYALEV For Adults Living Wi...
Benzinga Newsdesk
Bernstein Initiates Coverage On AbbVie with M...
Benzinga Newsdesk
Monday, October 14, 2024
Looking Into AbbVie's Recent Short Interest
Benzinga Insights
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Vandana Singh
Thursday, October 10, 2024
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Benzinga Insights
Truist Securities Maintains Buy on AbbVie, Ra...
Benzinga Newsdesk
Wednesday, October 09, 2024
UBS Maintains Neutral on AbbVie, Raises Price...
Benzinga Newsdesk
AbbVie's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Tuesday, October 08, 2024
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Vandana Singh
Monday, October 07, 2024
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Benzinga Insights
Barclays Maintains Overweight on AbbVie, Rais...
Benzinga Newsdesk
TD Cowen Maintains Buy on AbbVie, Raises Pric...
Benzinga Newsdesk
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
Thursday, October 03, 2024
Abbvie SAys Q3 2024 Adj Diluted EPS Guidance ...
Benzinga Newsdesk
AbbVie Reported GAAP & Adjusted Non-GAAP Earn...
Benzinga Newsdesk
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Vandana Singh
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch